About the Company
Imagin Medical is a Surgical Imaging Company
Cancer is much more than a statistic when it becomes your diagnosis or that of a loved one.
Bladder cancer is the sixth most prevalent cancer in the U.S. and the third most prevalent cancer in men. In addition to being one of the most expensive cancers to treat, it has the highest recurrence rate of all cancers at 50%, leaving some 600,000 people in the U.S. in fear that their bladder cancer will return.
Imagin Medical is developing the i/Blue™ Imaging System to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. Using innovative optic and light sensor technology, the i/Blue System combines the advantages of white and blue light cystoscopy with fluorescing contrast agents to simultaneously display white and blue light images on the surgical monitor, side-by-side, in real-time. Based on functional prototype demonstrations, leading urologists have indicated that this feature could make bladder cancer detection and removal more accurate and efficient, potentially reducing recurrence rates.
Based in Boston, Imagin’s experienced management team is advancing the i/Blue Imaging System’s development toward commercialization. Functional units are currently being tested by an independent lab to assure compliance with safety and performance regulations, and with a defined the regulatory path, the FDA approval process is underway. Imagin’s intellectual property is well-protected with additional patents being filed based on final design developments.
Imagin intends to build on the i/Blue technology, which currently works with hexaminolevulinate hydrochloride (HAL), and adapt it to other FDA-approved contrast agents, such as Indocyanine green (ICG). These additional products will expand Imagin’s market potential, facilitating entry into multiple endoscopic procedures, such as laparoscopic (general and gynecology), colorectal and thoracic.